抗小鼠PD-L1抗体(10F.9G2.1) ，体内实验级重组，大鼠IgG2b Kappa | Syd Labs PA007164.r2b

描述

了解更多抗小鼠PD-L1单克隆抗体（clone：10F.9G2）引用文献，请查看：抗小鼠PD-L1单抗（克隆号10F.9G2）引用文献

抗小鼠PD-L1抗体（10F.9G2）参考文献:

1. A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx)
Linlin Guo,et al.Oncoimmunology. 2022.PMCID: PMC9542669
“Blockade of checkpoint receptors with monoclonal antibodies against CTLA-4, PD-1 and PD-L1 has shown great clinical success in several cancer subtypes, yielding unprecedented responses albeit a significant number of patients develop resistance and remain refractory. Both PD-1/PD-L1 and HER-2 signaling pathway inhibitors have limited efficacy and exhibits significant toxicities that limit their use. Ongoing clinical studies support the need for rationale combination of immuno-oncology agents to make a significant impact in the lives of cancer patients. We introduce the development of a novel chimeric PD-L1 B-cell peptide epitope vaccine (amino acid 130–147) linked to a “promiscuous” T cell measles virus fusion (MVF) peptide (MVF-PD-L1(130); PDL1-Vaxx) or linked to tetanus toxoid (TT3) TT3-PD-L1 (130) via a linker (GPSL). These vaccine constructs are highly immunogenic and antigenic in several syngeneic animal models. The PD-L1 vaccines elicited high titers of polyclonal antibodies that inhibit tumor growth in multiple syngeneic cancer models, eliciting antibodies of different subtypes IgG1, IgG2a, IgG2b and IgG3, induced PD-1/PD-L1 blockade, decreased proliferation, induced apoptosis and caused ADCC of tumor cells. The PDL1-Vaxx induces similar inhibition of tumor growth versus the standard anti-mouse PD-L1 antibody in both syngeneic BALB/c and C57BL/6J mouse models. The combination of PDL1-Vaxx with HER-2 vaccine B-Vaxx demonstrated synergistic tumor inhibition in D2F2/E2 carcinoma cell line. The anti-PDL1-Vaxx block PD-1/PD-L1 interaction and significantly prolonged anti-tumor responses in multiple syngeneic tumor models. The combination of HER-2 vaccine
2. Lymph node and tumor-associated PD-L1+ macrophages antagonize dendritic cell vaccines by suppressing CD8+ T cells
Jenny Sprooten,et al.Cell Rep Med. 2024.PMCID: PMC10829875
“Current immunotherapies provide limited benefits against T cell-depleted tumors, calling for therapeutic innovation. Using multi-omics integration of cancer patient data, we predict a type I interferon (IFN) responseHIGH state of dendritic cell (DC) vaccines, with efficacious clinical impact. However, preclinical DC vaccines recapitulating this state by combining immunogenic cancer cell death with induction of type I IFN responses fail to regress mouse tumors lacking T cell infiltrates. Here, in lymph nodes (LNs), instead of activating CD4+/CD8+ T cells, DCs stimulate immunosuppressive programmed death-ligand 1-positive (PD-L1+) LN-associated macrophages (LAMs). Moreover, DC vaccines also stimulate PD-L1+ tumor-associated macrophages (TAMs). This creates two anatomically distinct niches of PD-L1+ macrophages that suppress CD8+ T cells. Accordingly, a combination of PD-L1 blockade with DC vaccines achieves significant tumor regression by depleting PD-L1+ macrophages, suppressing myeloid inflammation, and de-inhibiting effector/stem-like memory T cells. Importantly, clinical DC vaccines also potentiate T cell-suppressive PD-L1+ TAMs in glioblastoma patients. We propose that a multimodal immunotherapy and vaccination regimen is mandatory to overcome T cell-depleted tumors.”
3. Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer
Darren J. Schofield,et al.MAbs. 2021.PMCID: PMC7831362
“Preclinical studies of PD-L1 and CTLA-4 blockade have relied heavily on mouse syngeneic tumor models with intact immune systems, which facilitate dissection of immunosuppressive mechanisms in the tumor microenvironment. Commercially developed monoclonal antibodies (mAbs) targeting human PD-L1, PD-1, and CTLA-4 may not demonstrate cross-reactive binding to their mouse orthologs, and surrogate anti-mouse antibodies are often used in their place to inhibit these immune checkpoints. In each case, multiple choices exist for surrogate antibodies, which differ with respect to species of origin, affinity, and effector function. To develop relevant murine surrogate antibodies for the anti-human PD-L1 mAb durvalumab and the anti-human CTLA-4 mAb tremelimumab, rat/mouse chimeric or fully murine mAbs engineered for reduced effector function were developed and compared with durvalumab and tremelimumab. Characterization included determination of target affinity, in vivo effector function, pharmacokinetic profile, and anti-tumor efficacy in mouse syngeneic tumor models. Results showed that anti–PD-L1 and anti–CTLA-4 murine surrogates with pharmacologic properties similar to those of durvalumab and tremelimumab demonstrated anti-tumor activity in a subset of commonly used mouse syngeneic tumor models. This activity was not entirely dependent on antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis effector function, or regulatory T-cell depletion, as antibodies engineered to lack these features showed activity in models historically sensitive to checkpoint inhibition, albeit at a significantly lower level than antibodies with intact effector function.”

Syd Labs抗小鼠PD-L1重组抗体（克隆号10F.9G2.1）（货号：PA007164.r2b）推荐同型对照抗体:

重组大鼠IgG2b同型对照抗体，体内实验级（In vivo Grade Recombinant Rat IgG2b Isotype Control Antibody）

Syd Labs还提供以下重组IgG同型对照抗体:

重组小鼠IgG1同型对照抗体和突变体，体内实验级（In vivo Grade Recombinant Mouse IgG1 Isotype Control Antibody and Mutants）
重组小鼠IgG2a同型对照抗体和突变体，体内实验级（In vivo Grade Recombinant Mouse IgG2a Isotype Control Antibody and Mutants）
重组小鼠IgG2c同型对照抗体和突变体，体内实验级（In vivo Grade Recombinant Mouse IgG2c Isotype Control Antibody and Mutants）

Syd Labs提供以下抗小鼠PD-L1抗体和抗小鼠PD-1抗体（anti-mouse PD-L1 antibodies / anti-mouse PD-1 antibodies）:

重组抗小鼠PD-L1单克隆抗体（克隆号10F.9G2.1）（In Vivo Grade Recombinant Anti-mouse PD-L1 Monoclonal Antibody (Clone 10F.9G2.1)) 
重组抗小鼠PD1单克隆抗体（克隆号29F.1A12.1）（In vivo grade recombinant anti-mouse PD1 monoclonal antibodies （Clone 29F.1A12.1））
重组抗小鼠PD-1单克隆抗体（克隆号RMP1-14.1）（In vivo grade recombinant anti-mouse PD-1 monoclonal antibodies （Clone RMP1-14.1））
重组抗小鼠PD 1单克隆抗体（In Vivo Grade Recombinant Murinized Anti-mouse PD-1 Mouse Monoclonal Antibody (Clone RMP1-14.1)） 

Syd Labs提供以下体内实验级重组抗小鼠PD-L1单克隆抗体(克隆号10F.9G2.1)突变体:

体内实验级重组抗小鼠PD-L1小鼠IgG2c-L234A L235A P329G (LALAPG) Kappa单克隆抗体(克隆号10F.9G2.1)（In Vivo Grade Recombinant Anti-mouse PD-L1 Mouse IgG2c-L234A L235A P329G （LALAPG） Kappa Monoclonal Antibody （Clone 10F.9G2.1））
体内实验级重组抗小鼠PD-L1小鼠IgG2a-L234A L235A P329G (LALAPG) Kappa单克隆抗体(克隆号10F.9G2.1)（In Vivo Grade Recombinant Anti-mouse PD-L1 Mouse IgG2a-L234A L235A P329G （LALAPG）Kappa Monoclonal Antibody （Clone 10F.9G2.1））

关于PA007164.r2b Syd Labs抗小鼠PD-L1抗体您可能还会搜索:

PA007164.r2b Syd Labs抗小鼠PD-L1抗体
PA007164.m2cLA Syd Labs抗小鼠PD1抗体
PA007164.m2aLA Syd Labs抗小鼠PD-L1抗体
PA007164.m1DA Syd Labs抗小鼠PD-L1抗体
PA007164.m2b Syd Labs抗小鼠PD-L1抗体
PA007164.rt Syd Labs抗小鼠PD-L1抗体
PA007164.m2a Syd Labs抗小鼠PD-L1抗体
PA007164.m1 Syd Labs抗小鼠PD-L1抗体
PA007164.m2cLA 多找找
PA007164.m2cLA 10F.9G2.1
PA007164.m2cLA Syd Labs
be0101 bioxcell

请记住我们的产品信息: 抗小鼠PD-L1单克隆抗体,大鼠IgG2b Kappa,体内实验级重组(克隆号10F.9G2.1,货号：PA007164.r2b): PA007164.r2b Syd Labs In Vivo Grade Recombinant Anti-mouse PD-L1 Monoclonal Antibody (Clone 10F.9G2.1), Rat IgG2b Kappa。